JP2013518046A - 特定のキヌレニン−３−モノオキシゲナーゼインヒビターおよびその医薬組成物ならびにこれらの使用方法 - Google Patents

特定のキヌレニン−３−モノオキシゲナーゼインヒビターおよびその医薬組成物ならびにこれらの使用方法 Download PDF

Info

Publication number
JP2013518046A
JP2013518046A JP2012550116A JP2012550116A JP2013518046A JP 2013518046 A JP2013518046 A JP 2013518046A JP 2012550116 A JP2012550116 A JP 2012550116A JP 2012550116 A JP2012550116 A JP 2012550116A JP 2013518046 A JP2013518046 A JP 2013518046A
Authority
JP
Japan
Prior art keywords
phenyl
dichloro
pyrimidine
methyl
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012550116A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013518046A5 (enExample
Inventor
セリア ドミンゲス，
レティシア エム． トレド−シャーマン，
ディルク ヴィンクラー，
フレデリック ブルックフィールド，
アギア ペナ， パウラ セー． ドゥ
Original Assignee
シーエイチディーアイ ファウンデーション，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シーエイチディーアイ ファウンデーション，インコーポレーテッド filed Critical シーエイチディーアイ ファウンデーション，インコーポレーテッド
Publication of JP2013518046A publication Critical patent/JP2013518046A/ja
Publication of JP2013518046A5 publication Critical patent/JP2013518046A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012550116A 2010-01-25 2011-01-20 特定のキヌレニン−３−モノオキシゲナーゼインヒビターおよびその医薬組成物ならびにこれらの使用方法 Pending JP2013518046A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29809510P 2010-01-25 2010-01-25
US61/298,095 2010-01-25
PCT/US2011/021890 WO2011091153A1 (en) 2010-01-25 2011-01-20 Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2013518046A true JP2013518046A (ja) 2013-05-20
JP2013518046A5 JP2013518046A5 (enExample) 2013-12-19

Family

ID=44307208

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012550116A Pending JP2013518046A (ja) 2010-01-25 2011-01-20 特定のキヌレニン−３−モノオキシゲナーゼインヒビターおよびその医薬組成物ならびにこれらの使用方法

Country Status (15)

Country Link
US (1) US8883785B2 (enExample)
EP (1) EP2528441A4 (enExample)
JP (1) JP2013518046A (enExample)
KR (1) KR20120131161A (enExample)
CN (1) CN102811620B (enExample)
AU (1) AU2011207229B2 (enExample)
BR (1) BR112012018500A2 (enExample)
CA (1) CA2787365A1 (enExample)
MX (1) MX2012008346A (enExample)
NZ (1) NZ601547A (enExample)
PH (1) PH12012501480A1 (enExample)
RU (1) RU2012133475A (enExample)
SG (1) SG182534A1 (enExample)
WO (1) WO2011091153A1 (enExample)
ZA (1) ZA201206223B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018220762A1 (ja) * 2017-05-31 2018-12-06 大塚製薬株式会社 ピリミジン化合物
JP2020094045A (ja) * 2018-11-30 2020-06-18 大塚製薬株式会社 ピリミジン化合物の医薬用途
US12391674B2 (en) 2018-11-30 2025-08-19 Otsuka Pharmaceutical Co., Ltd. Heterocyclic compounds for the treatment of epilepsy

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010011302A1 (en) * 2008-07-22 2010-01-28 Chdi, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
BRPI0916576A2 (pt) 2008-08-04 2017-06-27 Chdi Inc pelo menos uma entidade química, composição farmacêutica, e, método para tratar uma condição ou distúrbio.
NZ601547A (en) 2010-01-25 2014-04-30 Chdi Foundation Inc Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
JP2012041325A (ja) * 2010-08-23 2012-03-01 Bayer Cropscience Ag オキサジアゾリノン誘導体およびその有害生物の防除用途
CN103619171B (zh) 2010-11-03 2015-11-25 陶氏益农公司 杀虫组合物和与其相关的方法
EP2651405A2 (en) * 2010-12-14 2013-10-23 Electrophoretics Limited Casein kinase 1 (ck1 ) inhibitors
PH12014500239A1 (en) * 2011-07-28 2014-03-31 Chdi Foundation Inc Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
SG2014012926A (en) * 2011-08-30 2014-06-27 Chdi Foundation Inc Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2013033068A1 (en) 2011-08-30 2013-03-07 Stephen Martin Courtney Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2013052526A1 (en) * 2011-10-06 2013-04-11 Merck Sharp & Dohme Corp. Triazolyl pde10 inhibitors
CN104010505B (zh) 2011-10-26 2017-03-15 陶氏益农公司 杀虫组合物和与其相关的方法
US9282739B2 (en) 2012-04-27 2016-03-15 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
CA2870090A1 (en) 2012-04-27 2013-10-31 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
US9708288B2 (en) 2012-04-27 2017-07-18 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
JP6603649B2 (ja) * 2013-03-14 2019-11-06 キュラデブ ファーマ プライベート リミテッド キヌレニン経路の阻害剤
GB201312800D0 (en) 2013-07-17 2013-08-28 Heptares Therapeutics Ltd mGlu5 modulators
WO2015058024A1 (en) 2013-10-17 2015-04-23 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
KR20160072155A (ko) 2013-10-17 2016-06-22 다우 아그로사이언시즈 엘엘씨 살충성 화합물의 제조 방법
MX2016004941A (es) 2013-10-17 2016-06-28 Dow Agrosciences Llc Proceso para la preparacion de compuestos plaguicidas.
US9029554B1 (en) 2013-10-17 2015-05-12 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
BR112016007518A2 (pt) 2013-10-17 2017-08-01 Dow Agrosciences Llc processos para a preparação de compostos pesticidas
CN105636441B (zh) 2013-10-17 2018-06-15 美国陶氏益农公司 制备杀虫化合物的方法
US9085564B2 (en) 2013-10-17 2015-07-21 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
NZ719634A (en) 2013-10-22 2017-09-29 Dow Agrosciences Llc Pesticidal compositions and related methods
US9788546B2 (en) 2013-10-22 2017-10-17 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
US9144241B2 (en) 2013-10-22 2015-09-29 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
CN105792651A (zh) 2013-10-22 2016-07-20 美国陶氏益农公司 杀虫组合物和与其相关的方法
AR098102A1 (es) 2013-10-22 2016-05-04 Dow Agrosciences Llc Composiciones plaguicidas y métodos relacionados
KR20160077113A (ko) 2013-10-22 2016-07-01 다우 아그로사이언시즈 엘엘씨 살충 조성물 및 관련 방법
EP3060045A4 (en) 2013-10-22 2017-04-05 Dow AgroSciences LLC Synergistic pesticidal compositions and related methods
US9801383B2 (en) 2013-10-22 2017-10-31 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
CN105658062A (zh) 2013-10-22 2016-06-08 美国陶氏益农公司 协同杀虫组合物和相关方法
TW201519774A (zh) 2013-10-22 2015-06-01 Dow Agrosciences Llc 協同性殺蟲組成物及相關方法（六）
EP3060043B1 (en) 2013-10-22 2025-11-26 Corteva Agriscience LLC Pesticidal compositions and related methods
WO2015061175A1 (en) 2013-10-22 2015-04-30 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
US9149040B2 (en) 2013-10-22 2015-10-06 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
RU2016119359A (ru) 2013-10-22 2017-11-28 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Синергетические пестицидные композиции и связанные с ними способы
CN105828608A (zh) 2013-10-22 2016-08-03 美国陶氏益农公司 杀虫组合物和与其相关的方法
AU2014340437B2 (en) 2013-10-22 2017-09-07 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
JP2016534086A (ja) 2013-10-22 2016-11-04 ダウ アグロサイエンシィズ エルエルシー 相乗的有害生物防除組成物および関連する方法
GB201322512D0 (en) 2013-12-19 2014-02-05 Glaxosmithkline Ip Dev Ltd Novel compounds
CN109678791B (zh) 2014-03-19 2022-07-01 美国陶氏益农公司 1-(2,4-二氟苯)-2,2-二氟-2-(5-取代吡啶-2-基)乙酮及制备方法
MX372995B (es) 2014-07-17 2020-04-13 Chdi Foundation Inc Metodos y composiciones para el tratamiento de trastornos relacionados con vih.
CA2954747A1 (en) 2014-07-31 2016-02-04 Dow Agrosciences Lcc Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
US9029555B1 (en) 2014-07-31 2015-05-12 Dow Agrosciences Llc Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine
CA2954631A1 (en) 2014-07-31 2016-02-04 Dow Agrosciences Llc Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
BR112017002735A2 (pt) 2014-08-19 2017-12-19 Dow Agrosciences Llc processo para a preparação de 3-(3-cloro-1h-pirazol-1-il)piridina
KR20170058388A (ko) 2014-09-12 2017-05-26 다우 아그로사이언시즈 엘엘씨 3-(3-클로로-1h-피라졸-1-일)피리딘의 제조 방법
CN107108594B (zh) * 2014-12-19 2020-06-09 葛兰素史密斯克莱知识产权发展有限公司 用作犬尿氨酸单加氧酶抑制剂的化合物
GB201508864D0 (en) 2015-05-22 2015-07-01 Glaxosmithkline Ip Dev Ltd Compounds
GB201508857D0 (en) 2015-05-22 2015-07-01 Glaxosmithkline Ip Dev Ltd Compounds
EP3525803B1 (en) 2016-10-13 2022-12-07 Juno Therapeutics, Inc. Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
WO2018118781A1 (en) * 2016-12-20 2018-06-28 Fmc Corporation Fungicidal oxadiazoles
WO2018125817A1 (en) 2016-12-29 2018-07-05 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
CN110139853B (zh) 2016-12-29 2023-06-16 美国陶氏益农公司 用于制备杀有害生物化合物的方法
US20210041460A1 (en) * 2018-03-19 2021-02-11 Fujifilm Wako Pure Chemical Corporation Method for judging psychiatric disorder
US11911376B2 (en) 2020-03-30 2024-02-27 The Regents Of The University Of Colorado Methods for preventing and treating retinal damage
BR112023002139A2 (pt) 2020-08-06 2023-04-18 Chdi Foundation Inc Compostos de heterobiarila e agentes de imageamento para proteína huntingtina
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
PL450605A1 (pl) 2024-12-16 2026-06-22 Uniwersytet Łódzki Zastosowanie inhibitorów enzymów szlaku kynureninowego jako regulatora wzrostu Trichophyton rubrum do zapobiegania lub leczenia grzybic, zwłaszcza wywołanych Trichophyton rubrum

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6144872A (ja) * 1984-07-13 1986-03-04 Fujisawa Pharmaceut Co Ltd ピリミジン誘導体およびそれを含有する医薬組成物
JPS62120382A (ja) * 1985-11-09 1987-06-01 バイエル・アクチエンゲゼルシヤフト ニコチン酸誘導体
DE4031798A1 (de) * 1990-10-08 1992-04-09 Hoechst Ag Pyridylpyrimidine, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide
JP2006514043A (ja) * 2002-12-20 2006-04-27 ファルマシア・コーポレーション マイトジェン活性化タンパク質キナーゼ−活性化タンパク質キナーゼ−２を阻害する化合物
JP2006515313A (ja) * 2002-11-15 2006-05-25 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼのインヒビターとして有用なジアミノトリアゾール
JP2006521357A (ja) * 2003-03-24 2006-09-21 メルク　エンド　カムパニー　インコーポレーテッド ナトリウムチャンネル遮断薬としてのビアリール置換６員複素環化合物
JP2007243101A (ja) * 2006-03-13 2007-09-20 Konica Minolta Holdings Inc 有機エレクトロルミネッセンス素子材料、有機エレクトロルミネッセンス素子、表示装置及び照明装置
JP2008074751A (ja) * 2006-09-20 2008-04-03 Taiho Yakuhin Kogyo Kk フェニルピリミジン化合物又はその塩、及びその用途
JP2008530012A (ja) * 2005-02-04 2008-08-07 ブリストル−マイヤーズ スクイブ カンパニー キナーゼインヒビターとして有用な、フェニル置換ピリミジン化合物
JP2008218986A (ja) * 2007-02-06 2008-09-18 Sumitomo Chemical Co Ltd 組成物及び該組成物を用いてなる発光素子
WO2009048101A1 (ja) * 2007-10-10 2009-04-16 Takeda Pharmaceutical Company Limited アミド化合物
WO2010064597A1 (ja) * 2008-12-01 2010-06-10 武田薬品工業株式会社 ピペリジン誘導体
JP2011001347A (ja) * 2009-05-18 2011-01-06 Sumitomo Chemical Co Ltd ピリミジン化合物及びその有害生物の防除用途

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3707560A (en) * 1970-10-05 1972-12-26 Pfizer Certain 4-amino-6-aryl-pyrimidines
DE3623302A1 (de) * 1985-11-09 1987-05-14 Bayer Ag Nicotinsaeurederivate
DE3609596A1 (de) * 1986-03-21 1987-10-01 Hoechst Ag 2-azolylmethyl-2-aryl-1,3-dioxolane und deren salze, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung
MX16687A (es) * 1988-07-07 1994-01-31 Ciba Geigy Ag Compuestos de biarilo y procedimiento para su preparacion.
AU644159B2 (en) * 1990-05-17 1993-12-02 Novartis Ag 2-anilino-4-cyanopyrimidine derivatives
DE19600934A1 (de) * 1996-01-12 1997-07-17 Basf Ag Substituierte Aza- und Diazacycloheptan- und Cyclooctanverbindungen und deren Verwendung
US6610723B2 (en) 2001-01-29 2003-08-26 Hoffmann-La Roche Inc. Imidazole derivatives
US6552188B2 (en) 2001-06-29 2003-04-22 Kowa Co., Ltd. Unsymmetrical cyclic diamine compound
AR037233A1 (es) 2001-09-07 2004-11-03 Euro Celtique Sa Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento
US6949542B2 (en) 2002-02-06 2005-09-27 Hoffman-La Roche Inc. Dihydro-benzo[b][1,4]diazepin-2-one derivatives
US7122580B2 (en) 2002-08-09 2006-10-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds and methods to modulate coagulation
AU2003280558A1 (en) 2002-10-11 2004-05-04 Kowa Co., Ltd. Method for treatment of cancer
SE0301963D0 (sv) 2003-07-02 2003-07-02 Astrazeneca Ab New compounds
WO2005012286A1 (en) 2003-07-25 2005-02-10 Amgen Inc. Substituted pyridones and pyrimidinones with antiinflammatory properties
JPWO2005040135A1 (ja) 2003-10-24 2007-03-08 小野薬品工業株式会社 抗ストレス薬およびその医薬用途
EP1678149A2 (en) 2003-10-31 2006-07-12 Neurogen Corporation 4-amino(aza)quinoline derivatives as capsaicin receptor agonists
ATE509011T1 (de) 2004-06-28 2011-05-15 Hoffmann La Roche Pyrimidinderivate als 11beta-hsd1-inhibitoren
DE602005016272D1 (de) 2004-08-27 2009-10-08 Astellas Pharma Inc 2-phenylpyridinderivat
CA2578122A1 (en) * 2004-08-27 2006-03-02 Gpc Biotech Ag Pyrimidine derivatives
EP1820795A4 (en) 2004-12-07 2010-10-20 Toyama Chemical Co Ltd NEW ANTHRANILIC ACID DERIVATIVE OR SALT FROM IT
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US20060223849A1 (en) 2005-03-14 2006-10-05 Mjalli Adnan M Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors
US7345178B2 (en) 2005-08-04 2008-03-18 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
EP1912970A2 (en) 2005-08-10 2008-04-23 Bayer Schering Pharma Aktiengesellschaft Acyltryptophanols for fertility control
CN101291908A (zh) 2005-08-23 2008-10-22 Irm责任有限公司 免疫抑制剂化合物和组合物
TW200745055A (en) * 2005-09-23 2007-12-16 Organon Nv 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
JP2009518442A (ja) 2005-12-05 2009-05-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性エポキシド加水分解酵素インヒビターとして有益な置換ピラゾール化合物
AU2006325746A1 (en) 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
US7951824B2 (en) 2006-02-17 2011-05-31 Hoffman-La Roche Inc. 4-aryl-pyridine-2-carboxyamide derivatives
JP2007230963A (ja) 2006-03-03 2007-09-13 Daiso Co Ltd ２，４−ジ置換ピリジンの製造法
NZ623002A (en) 2006-06-26 2015-08-28 Akebia Therapeutics Inc Prolyl hydroxylase inhibitors and methods of use
WO2008022281A1 (en) * 2006-08-16 2008-02-21 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Small molecule inhibitors of kynurenine-3-monooxygenase
WO2008022286A2 (en) * 2006-08-16 2008-02-21 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Small molecule inhibitors of kynurenine-3-monooxygenase
JPWO2008023720A1 (ja) 2006-08-23 2010-01-14 アステラス製薬株式会社 ウレア化合物又はその塩
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
WO2008095852A1 (en) 2007-02-08 2008-08-14 Respiratorius Ab Bronchorelaxing arylamides
EP2142498A2 (en) 2007-04-02 2010-01-13 Institute for Oneworld Health Cftr inhibitor compounds and uses thereof
EP2002834A1 (de) 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Aryl/Hetarylamide als Modulatoren des EP2-Rezeptors
CL2008001933A1 (es) 2007-06-29 2009-09-25 Millennium Pharm Inc Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros.
PE20091309A1 (es) 2007-12-21 2009-09-30 Astrazeneca Ab Derivados de ciclohexilo como inhibidores de acetil coenzima a carboxilasa
JP2009280521A (ja) 2008-05-22 2009-12-03 Daiso Co Ltd ２，４−ジ置換ピリジンの製造法
JP2011184298A (ja) 2008-06-02 2011-09-22 Sanwa Kagaku Kenkyusho Co Ltd 新規化合物及びその医薬用途
US20110118262A1 (en) 2008-07-08 2011-05-19 Boehringer Ingelheim International Gmbh Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors
BRPI0916576A2 (pt) * 2008-08-04 2017-06-27 Chdi Inc pelo menos uma entidade química, composição farmacêutica, e, método para tratar uma condição ou distúrbio.
WO2010100475A1 (en) 2009-03-02 2010-09-10 Astrazeneca Ab Hydroxamic acid derivatives as gram-negative antibacterial agents
UY32543A (es) 2009-04-07 2010-11-30 Astrazeneca Ab Análogos de isoxazol-3(2h)-ona como agentes terapéuticos
TWI625121B (zh) 2009-07-13 2018-06-01 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
CA2777043C (en) 2009-10-14 2015-12-15 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
EP2490530A4 (en) 2009-10-22 2014-01-22 Univ Washington COMPOUNDS AND METHOD FOR THE TREATMENT OF BACTERIAL INFECTIONS
NZ601547A (en) 2010-01-25 2014-04-30 Chdi Foundation Inc Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
ES2635340T3 (es) 2010-02-27 2017-10-03 Bayer Intellectual Property Gmbh Ariltriazolonas ligadas a bis-arilo y su uso
US8440665B2 (en) 2010-07-02 2013-05-14 Gilead Sciences, Inc. Apoptosis signal-regulating kinase inhibitors
EP2616441B1 (en) 2010-09-17 2019-08-07 Purdue Pharma L.P. Pyridine compounds and the uses thereof

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6144872A (ja) * 1984-07-13 1986-03-04 Fujisawa Pharmaceut Co Ltd ピリミジン誘導体およびそれを含有する医薬組成物
JPS62120382A (ja) * 1985-11-09 1987-06-01 バイエル・アクチエンゲゼルシヤフト ニコチン酸誘導体
DE4031798A1 (de) * 1990-10-08 1992-04-09 Hoechst Ag Pyridylpyrimidine, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide
JP2006515313A (ja) * 2002-11-15 2006-05-25 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼのインヒビターとして有用なジアミノトリアゾール
JP2006514043A (ja) * 2002-12-20 2006-04-27 ファルマシア・コーポレーション マイトジェン活性化タンパク質キナーゼ−活性化タンパク質キナーゼ−２を阻害する化合物
JP2006521357A (ja) * 2003-03-24 2006-09-21 メルク　エンド　カムパニー　インコーポレーテッド ナトリウムチャンネル遮断薬としてのビアリール置換６員複素環化合物
JP2008530012A (ja) * 2005-02-04 2008-08-07 ブリストル−マイヤーズ スクイブ カンパニー キナーゼインヒビターとして有用な、フェニル置換ピリミジン化合物
JP2007243101A (ja) * 2006-03-13 2007-09-20 Konica Minolta Holdings Inc 有機エレクトロルミネッセンス素子材料、有機エレクトロルミネッセンス素子、表示装置及び照明装置
JP2008074751A (ja) * 2006-09-20 2008-04-03 Taiho Yakuhin Kogyo Kk フェニルピリミジン化合物又はその塩、及びその用途
JP2008218986A (ja) * 2007-02-06 2008-09-18 Sumitomo Chemical Co Ltd 組成物及び該組成物を用いてなる発光素子
WO2009048101A1 (ja) * 2007-10-10 2009-04-16 Takeda Pharmaceutical Company Limited アミド化合物
WO2010064597A1 (ja) * 2008-12-01 2010-06-10 武田薬品工業株式会社 ピペリジン誘導体
JP2011001347A (ja) * 2009-05-18 2011-01-06 Sumitomo Chemical Co Ltd ピリミジン化合物及びその有害生物の防除用途

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JPN7015000241; 薬学雑誌 Ｖ９０，　Ｐ８７０-８７６, 1970 *
JPN7015000242; ＴＥＴＲＡＨＥＤＲＯＮ　ＬＥＴＴＥＲＳ Ｖ１５，　Ｎｏ．２７，　Ｐ２３４７-２３５０, 1974 *
JPN7015000243; ＢＡＲＡＭ　ｅｔ　ａｌ．: ＳＥＲＩＹＡ　ＫＨＩＩＭＩＣＨＥＳＫＩＫＨ　ＮＡＵＫ , 1983, Ｐ１１１-１１７ *
JPN7015000244; ＫＲＩＶＯＰＡＬＯＶ　ｅｔ　ａｌ．: ＫＨＩＭＩＹＡ　ＧＥＴＥＲＯＴＳＩＫＬＩＣＨＥＳＫＩＫＨ　ＳＯＥＤＩＮＥＮＩＩ Ｖ９，　Ｐ１２２２-１２２６, 1983 *
JPN7015000245; ＴＥＴＲＡＨＥＤＲＯＮ　ＬＥＴＴＥＲＳ Ｖ４６，　Ｐ１６６３-１６６５, 2005 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018220762A1 (ja) * 2017-05-31 2018-12-06 大塚製薬株式会社 ピリミジン化合物
US10800758B2 (en) 2017-05-31 2020-10-13 Otsuka Pharmaceutical Co., Ltd. Pyrimidine compound
JP2020094045A (ja) * 2018-11-30 2020-06-18 大塚製薬株式会社 ピリミジン化合物の医薬用途
US12391674B2 (en) 2018-11-30 2025-08-19 Otsuka Pharmaceutical Co., Ltd. Heterocyclic compounds for the treatment of epilepsy

Also Published As

Publication number Publication date
EP2528441A1 (en) 2012-12-05
MX2012008346A (es) 2012-11-12
EP2528441A4 (en) 2013-07-10
NZ601547A (en) 2014-04-30
CN102811620B (zh) 2015-03-25
AU2011207229B2 (en) 2015-02-12
WO2011091153A1 (en) 2011-07-28
US20130029988A1 (en) 2013-01-31
BR112012018500A2 (pt) 2016-08-16
CN102811620A (zh) 2012-12-05
AU2011207229A1 (en) 2012-08-16
SG182534A1 (en) 2012-08-30
ZA201206223B (en) 2013-04-24
PH12012501480A1 (en) 2012-10-22
RU2012133475A (ru) 2014-03-10
KR20120131161A (ko) 2012-12-04
CA2787365A1 (en) 2011-07-28
US8883785B2 (en) 2014-11-11

Similar Documents

Publication Publication Date Title
US8883785B2 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US9649310B2 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
CN110156770B (zh) 作为tam族激酶抑制剂的氨基吡啶衍生物
JP5511379B2 (ja) Ｃｇｒｐレセプターアンタゴニスト
JP2020143136A (ja) 新規なフェロポーチン阻害剤
US7951957B2 (en) Substituted benzimidazoles and their use for inducing apoptosis
US20100297097A1 (en) Compounds
KR20140072037A (ko) 키뉴레닌-3-모노옥시게나제 억제제, 약학적 조성물 및 이의 사용 방법
AU2018201275A1 (en) Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmune inflammation and CNS disorders
WO2010007966A1 (ja) アゾール化合物
JP2022519770A (ja) ファルネソイドｘ受容体モジュレータとしての置換二環式化合物
JP6883045B2 (ja) オレキシン受容体調節因子としてのハロ置換ピペリジン
US20050171141A1 (en) Modulators of muscarinic receptors
JP2018529745A (ja) Ｎｒｆ２レギュレーターとしてのビアリールピラゾール
WO2000053582A1 (fr) COMPOSES HETEROCYCLIQUES POSSEDANT UN EFFET D'ACTIVATION DU RECEPTEUR α4β2 DE L'ACETYLCHOLINE NICOTINIQUE
WO2013055607A1 (en) Mineralocorticoid receptor antagonists
EP1636215A1 (en) Furazanobenzimidazoles
GB2263636A (en) Substituted triazolinones, triazolinethiones, and triazolinimines as neurotensin antagonists
JP2003119191A (ja) ベンゾアゼピン誘導体、その製造法および用途
JP2022521895A (ja) ファルネソイドｘ受容体モジュレータとしての置換二環式化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131028

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131028

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150129

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20150306

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150312

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150630